These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8586513)

  • 1. Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
    Dutkiewicz S; Witeska A; Stepień K
    Int Urol Nephrol; 1995; 27(4):413-7. PubMed ID: 8586513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
    Dutkiewicz S; Witeska A
    Int Urol Nephrol; 1995; 27(3):311-8. PubMed ID: 7591596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum PSA levels at 6 month after surgery, TURP or Doxazosin therapy for BPH.
    Dutkiewicz S; Stepień K
    Mater Med Pol; 1996; 28(2):69-70. PubMed ID: 9088130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxazosin for benign prostatic hyperplasia in primary care.
    Guthrie R
    Clin Ther; 1997; 19(6):1269-77; discussion 1253-4. PubMed ID: 9444439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R; Thalmann G; Reich O; Steif CG
    Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
    [No Abstract]   [Full Text] [Related]  

  • 8. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
    Jansen DJ; Resch ND; Hoffman RM
    Am J Health Syst Pharm; 1999 Jul; 56(13):1351. PubMed ID: 10683137
    [No Abstract]   [Full Text] [Related]  

  • 11. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
    Roehrborn CG; Oesterling JE; Olson PJ; Padley RJ
    Urology; 1997 Oct; 50(4):556-61. PubMed ID: 9338731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
    Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
    Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benign prostatic syndrome. 3-step plan for the treatment].
    MMW Fortschr Med; 2003 Sep; 145(39):52. PubMed ID: 14649077
    [No Abstract]   [Full Text] [Related]  

  • 14. [Alpha blockers in the treatment of benign hyperplasia of the prostate].
    Gómez Sancha F; Fernández Arjona M; Peinado Ibarra F; Fernández Borrell A; Mínguez Martínez R; Pereira Sanz I
    Rev Clin Esp; 1997 May; 197(5):358-62. PubMed ID: 9280971
    [No Abstract]   [Full Text] [Related]  

  • 15. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
    Samli MM; Dincel C
    Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
    Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
    J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The early effects of doxazosin on benign prostatic hyperplasia.
    Akan H; Başar M; Dalva I; Başar H
    Arch Ital Urol Androl; 1998 Feb; 70(1):41-4. PubMed ID: 9549168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
    Fawzy A; Hendry A; Cook E; Gonzalez F
    Int J Urol; 1999 Jul; 6(7):346-54. PubMed ID: 10445304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up.
    Dutkiewicz S
    Int Urol Nephrol; 2004; 36(2):169-73. PubMed ID: 15368687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.